Zai Lab Ltd (HK:9688) has released an update. Zai Lab Ltd is set to offer 7,843,137 American Depositary Shares (ADS), representing 78,431,370 ...

Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...

Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced th ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 46%. Looking ahead, ...

Zai Lab Ltd (HK:9688) has released an update. Zai Lab Limited has announced a proposed follow-on underwritten public offering of $200 million ...

Zai Lab (NASDAQ:ZLAB) stock rose 5% in early trading Monday after the company announced that Vyvgart Hytrulo’s regulatory ...

Zai Lab Ltd (HK:9688) has released an update. Zai Lab Limited has updated its risk factors in a new Form 8-K filing with the U.S. Securities ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zai Lab (ZLAB – Research Report), NeuroPace (NPCE – Research Report) and CervoMed (CRVO – Research ...

The business’s 50 day simple moving average is $25.16 and its 200 day simple moving average is $20.68. Zai Lab has a 1 year ...

Zai Lab Ltd ( (ZLAB)) has released its Q3 earnings. Here is a breakdown of the information Zai Lab Ltd presented to its investors. Zai Lab Limited is a biopharmaceutical company based in China and the ...

Limited announced that it has commenced an underwritten public offering of $200M of American depositary shares, ADSs, each ...